论文部分内容阅读
目的探讨β3肾上腺素受体(β3-adrenergic receptor,β3-AR)Trp64Arg基因变异在中国健康人群和2型糖尿病(type2diabetes,T2DM)患者中的分布频率,查明该遗传多态性对罗格列酮在T2DM患者中疗效的影响。方法采用聚合酶链式反应-限制性片断长度多态性(polymerase chainreaction-restriction fragment length polymorphism,PCR-RFLP)对255名T2DM患者和148名健康对照者进行β3-ARTrp64Arg基因型分析,并在T2DM组中随机选取34名患者每天口服4mg罗格列酮,持续12wk。服药前和服药第12周末进行血糖、血胰岛素以及糖化血红蛋白等指标的测定。结果β3-AR Trp64Arg等位基因的发生频率符合Hardy-Wein-berg平衡,64Arg等位基因在T2DM组和健康对照组的频率分别为0.13和0.17。罗格列酮治疗12wk后,Trp64Arg基因型患者甘油三酯的下降值低于Trp64Trp型患者(P<0.05),但后者对低密度脂蛋白胆固醇(P<0.01)与脂联素(P<0.05)的作用优于Trp64Arg基因型患者。结论β3-AR Trp64Arg遗传多态性与中国汉族人群T2DM发病无明显相关性,但对2型糖尿病中罗格列酮的疗效存在一定影响。
Objective To investigate the frequency of Trp64Arg gene mutation in β3-adrenergic receptor (β3-AR) in Chinese healthy people and type 2 diabetes (T2DM) Effect of ketones in patients with T2DM. Methods The genotypes of β3-ARTrp64Arg in 255 T2DM patients and 148 healthy controls were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) 34 patients were randomized to receive 4 mg of rosiglitazone daily for 12 weeks. Pretreatment and medication at the end of the twelfth week of blood glucose, insulin and glycosylated hemoglobin and other indicators of measurement. Results The frequency of β3-AR Trp64Arg allele was in accordance with Hardy-Wein-berg equilibrium. The frequencies of 64Arg allele in T2DM group and healthy control group were 0.13 and 0.17, respectively. After 12 weeks of rosiglitazone treatment, the decline of triglyceride in patients with Trp64Arg genotype was lower than that of Trp64Trp patients (P <0.05), but the latter was negative for low density lipoprotein cholesterol (P <0.01) and adiponectin (P < 0.05) is better than Trp64Arg genotype patients. Conclusion The genetic polymorphism of β3-AR Trp64Arg has no significant correlation with the incidence of T2DM in Chinese Han population, but there is some effect on the efficacy of rosiglitazone in type 2 diabetes mellitus.